Provider-based research networks may improve early access to innovative colon cancer treatment for african americans treated in the community

Cancer

Volumn 121, Issue 1, 2015, Pages 93-101

  Penn, Dolly C ^a   Chang, Yunkyung ^b   Meyer, Anne Marie ^b,c   MacK, Christina Defilippo ^c   Sanoff, Hanna K ^a   Stitzenberg, Karyn B ^a,b   Carpenter, William R ^b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c IL   (United States)

Author keywords

Aged; Colon cancer; Colonic neoplasms therapy; Community institutional relations; End Results (SEER) program; Epidemiology; Health care disparities; Oxaliplatin; Surveillance

Indexed keywords

OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTICLE; CANCER STAGING; CLINICAL EFFECTIVENESS; COLON CANCER; COMMUNITY CLINICAL ONCOLOGY PROGRAM; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MEDICAL SERVICE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PROGRAM DEVELOPMENT; RACE DIFFERENCE; VERY ELDERLY; COHORT ANALYSIS; COLONIC NEOPLASMS; COMMUNITY CARE; ETHNOLOGY; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; NATIONAL HEALTH ORGANIZATION; ORGANIZATION AND MANAGEMENT; PATHOLOGY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COLONIC NEOPLASMS; COMMUNITY NETWORKS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; MALE; NATIONAL CANCER INSTITUTE (U.S.); ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84918831446     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29028     Document Type: Article

References (57)

1. Colon Cancer Alliance. Colon Cancer Statistics. ccalliance.org/color-ectal-cancer/statistics.html. Accessed June 27, 2013.
2. American Cancer Society. Colorectal Cancer. cancer.org/cancer/colo-nandrectumcancer/detailedguide/colorectal-cancer-key-statistics. Accessed March 3, 2014.
3. American Cancer Society. Colorectal Cancer Facts & Figures 2011-2013. cancer.org/acs/groups/content/@epidemiologysurveilance/docu ments/document/acspc-028323.pdf. Accessed July 3, 2013.
4. Phatak UR, Kao LS, Millas SG, Wiatrek RL, Ko TC, Wray CJ. Interaction between age and race alters predicted survival in colo-rectal cancer. Ann Surg Oncol. 2013;20:3363-3369.
5. Baldwin L, Dobie SA, Billingsley K, et al. Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst. 2005;97:1211-1212.
6. Berry J, Caplan L, Davis S, et al. A black-white comparison of the quality of stage-specific colon cancer treatment. Cancer. 2010;116: 713-722.
7. Berry J, Bumpers K, Ogunlade V, et al. Examining racial disparities in colorectal cancer care. J Psychosoc Oncol. 2009;27:59-83.
8. Grubbs SS, Polite BN, Carney J, et al. Eliminating racial disparities in colorectal cancer in the real world: it took a village. J Clin Oncol. 2013;31:1928-1930.
9. Ahmed NU, Pelletier V, Winter K, Albatineh AN. Factors explaining racial/ethnic disparities in rates of physician recommendation for colorectal cancer screening. Am J Public Health. 2013;103:e91-e99.
10. Laiyemo AO, Doubeni C, Pinsky PF, et al. Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst. 2010;102:538-546.
11. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol. 2006;24:2179-2187.
12. Chien C, Morimoto LM, Tom J, et al. Differences in colorectal carcinoma stage and survival by race and ethnicity. Cancer. 2005;104: 629-639.
13. Wallace K, Hill EG, Lewin DN, et al. Racial disparities in advanced-stage colorectal cancer survival. Cancer Causes Control. 2013;24:463-471.
14. Sineshaw HM, Robbins AS, Jemal A. Disparities in survival improvement for metastatic colorectal cancer by race/ethnicity and age in the United States. Cancer Causes Control. 2014;25:419-423.
15. Yothers G, Sargent DJ, Wolmark N, et al; Accent Collaborative Group. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011;103:1498-1506.
16. Dominitz JA, Samsa GP, Landsman P, Provenzale D. Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system. Cancer. 1998;82:2312-2320.
17. Andaya AA, Enewold L, Zahm SH, et al. Race and colon cancer survival in an equal-access health care system. Cancer Epidemiol Bio-markers Prev. 2013;22:1030-1036.
18. Carpenter WR, Meyer AM, Wu Y, et al. Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation. Med Care. 2012;50:737-748.
19. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109-3116.
20. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluoroura-cil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.
21. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxali-platin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465-1471.
22. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198-2204.
23. Sanoff HK, Carpenter WR, Freburger J, et al. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. Cancer. 2012;118:4309-4320.
24. Sanoff HK, Carpenter WR, Martin CF, et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst. 2012;104:211-227.
25. National Cancer Institute. About the SEER-Medicare Database Fact-sheet. seer.cancer.gov/about/factsheets/SEER-brochure.pdf. Accessed July 1, 2013.
26. Centers for Medicare and Medicaid Services. CMS Fast Facts Overview. cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/CMS-Fast-Facts/index.html. Accessed July 1, 2013.
27. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444-1450.
28. National Comprehensive Cancer Network. NCCN Guidelines for Treatment of Cancer by Site: Colon Cancer. nccn.org/professionals/physician-gls/f-guidelines.asp#site. Accessed December 5, 2012.
29. Zedan AH, Hansen TF, Fex Svenningsen A, Vilholm OJ. Oxalipla-tin-induced neuropathy in colorectal cancer: many questions with few answers. Clin Colorectal Cancer. 2014;13:73-80.
30. Hermosillo-Rodriguez J, Anaya DA, Sada Y, et al. The effect of age and comorbidity on patient-centered health outcomes in patients receiving adjuvant chemotherapy for colon cancer. J Geriatr Oncol. 2013;4:99-106.
31. Klabunde CN, Legler JM, Warren JL, et al. A refined comorbidity measurement algorithm for claims-based studies of breast, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17:584-590.
32. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267.
33. Vandenbroucke JP, von Elm E, Altman DG, et al; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007; 4:e297.
34. Sanoff HK, McLeod HL. Predictive factors for response and toxicity in chemotherapy: pharmacogenomics. Semin Colon Rectal Surg. 2008;19:226-230.
35. Mack CD, Carpenter W, Meyer A, et al. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults. Cancer. 2012;118:2925-2934.
36. Carpenter WR, Godley PA, Clark JA, et al. Racial differences in trust and regular source of patient care and the implications for prostate cancer screening use. Cancer. 2009;115:5048-5059.
37. Stewart JH, Bertoni AG, Staten JL, Levine EA, Gross CP. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol. 2007;14:3328-3334.
38. Stallings FL, Ford ME, Simpson NK, et al; Prostate, Lung, Colo-rectal and Ovarian Cancer Screening Trial Project Team. Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(suppl 6):379S-389S.
39. Giuliano AR, Mokuau N, Hughes C, et al. Participation of minorities in cancer research: the influence of structural, cultural, and linguistic factors. Ann Epidemiol. 2000;10(suppl 8):S22-S34.
40. McCaskill-Stevens W, McKinney MM, Whitman CG, Minasian LM. Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experience. J Clin Oncol. 2005;23:5247-5254.
41. Carpenter WR, Reeder-Hayes K, Bainbridge J, et al. The role of organizational affiliations and research networks in the diffusion of breast cancer treatment innovation. Med Care. 2011;49:172-179.
42. Minasian LM, Carpenter WR, Weiner BJ, et al. Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program. Cancer. 2010;116:4440-4449.
43. Reeder-Hayes KE, Bainbridge J, Meyer AM, et al. Race and age disparities in receipt of sentinel lymph node biopsy for early-stage breast cancer. Breast Cancer Res Treat. 2011;128:863-871.
44. Breslin TM, Morris AM, Gu N, et al. Hospital factors and racial disparities in mortality after surgery for breast and colon cancer. J Clin Oncol. 2009;27:3945-3950.
45. Dorsey K, Zhou Z, Masaoud R, Nimeiri HS. Health care disparities in the treatment of colorectal cancer. Curr Treat Options Oncol. 2013;14:405-414.
46. Hashiguchi Y, Hase K, Ueno H, et al. Impact of race/ethnicity on prognosis in patients who underwent surgery for colon cancer: analysis for white, African, and East Asian Americans. Ann Surg Oncol. 2012;19:1517-1528.
47. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573.
48. Blackman DJ, Masi CM. Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes? J Clin Oncol. 2006;24:2170-2178.
49. Dimou A, Strigos KN, Saif MW. Disparities in colorectal cancer in African-Americans vs whites: before and after diagnosis. World J Gas-troenterol. 2009;15:3734-3743.
50. Sanoff HK, Sargent DJ, Green EM, et al. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol. 2009;27:4109-4115.
51. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26:5721-5727.
52. Lund JL, Sturmer T, Sanoff HK, Brookhart A, Sandler RS, Warren JL. Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients. Cancer. 2013;119:2038-2047.
53. Mack CD, Glynn RJ, Brookhart MA, et al. Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy. Pharmacoepidemiol Drug Saf. 2013;22: 810-818.
54. Tournigand C, Andre T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol. 2012;30:3353-3360.
55. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002; 40(suppl 8):IV-19-25.
56. Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002;40(suppl 8):IV-43-8.
57. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and gen-eralizability to the United States elderly population. Med Care. 2002;40(suppl 8):IV-3-18.